Possible Treatment for Paroxysmal Nocturnal Hemoglobinuria Submitted for FDA Approval
jarmoluk / Pixabay

Possible Treatment for Paroxysmal Nocturnal Hemoglobinuria Submitted for FDA Approval

According to a story from Business Wire, the company Alexion Pharmaceuticals recently announced that it has submitted a Biologics License Application (BLA) to the FDA for the approval of one…

Continue Reading Possible Treatment for Paroxysmal Nocturnal Hemoglobinuria Submitted for FDA Approval
This New Program Can Help Make Life Easier for Rare Disease Patients
geraldoswald62 / Pixabay

This New Program Can Help Make Life Easier for Rare Disease Patients

According to a story from CheckOrphan, Express Scripts has prepared a Rare Conditions Care Value (RCCV) program. This program is designed to help make the diagnosis and treatment process for…

Continue Reading This New Program Can Help Make Life Easier for Rare Disease Patients
Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced
rawpixel / Pixabay

Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced

Data from a Phase II clinical trial of the experimental treatment reldesemtiv for the treatment of spinal muscular atrophy has been announced. The drug has shown positive effects in the…

Continue Reading Results From a Phase II Trial of Reldesemtiv For Treating Spinal Muscular Atrophy Have Been Announced
New Expanded Access Trials For FENIB and LOTS Patients Set to Begin
DarkoStojanovic / Pixabay

New Expanded Access Trials For FENIB and LOTS Patients Set to Begin

According to a story from globenewswire.com, the corporation Retrotope recently announced the initiation of single-patient, expanded access trials of its experimental product RT001. The patients involved have familial encephalopathy with neuroserpin…

Continue Reading New Expanded Access Trials For FENIB and LOTS Patients Set to Begin
A Gene Therapy Being Developed to Treat Duchenne Muscular Dystrophy Has Shown Exciting Results
qimono / Pixabay

A Gene Therapy Being Developed to Treat Duchenne Muscular Dystrophy Has Shown Exciting Results

An experimental gene therapy designed to treat Duchenne muscular dystrophy has produced exciting preliminary results in a Phase 1/2a clinical trial. Sarepta Therapeutics, the company behind the therapy’s development, announced…

Continue Reading A Gene Therapy Being Developed to Treat Duchenne Muscular Dystrophy Has Shown Exciting Results
A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released
mohamed_hassan / Pixabay

A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released

An open-label extension of a Phase II study has shown that the experimental drug lenabasum is fairly safe and tolerable in patients who have diffuse cutaneous systemic sclerosis. The full…

Continue Reading A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released
Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica
LionFive / Pixabay

Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica

According to a story from Newswise, a team of scientists and researchers have recently completed research that managed to reveal the genetic nature of the unusual rare disease neuromyelitis optica.…

Continue Reading Researchers Discover More Information on the Genetic Basis of Neuromyelitis Optica

Interim Data From a Study of a Sickle Cell Disease Gene Therapy Has Been Announced

The experimental gene therapy LentiGlobin for the treatment of severe sickle cell disease is being investigated in an ongoing Phase 1 clinical trial. Bluebird Bio, the company developing the therapy,…

Continue Reading Interim Data From a Study of a Sickle Cell Disease Gene Therapy Has Been Announced

Interim Results From a Study of a Potential Treatment For WHIM Syndrome Have Been Released

Clinical data from a Phase 2 study of the experimental drug X4P-001-RD for the treatment of WHIM syndrome has been announced at the European Hematology Association’s 23rdCongress in Stockholm. The…

Continue Reading Interim Results From a Study of a Potential Treatment For WHIM Syndrome Have Been Released

Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial

According to a story from globenewswire.com, the biopharmaceutical company Idera Pharmaceuticals recently released the data from its Phase 2 trial for IMO-8400, an investigational product in development for the treatment…

Continue Reading Experimental Treatment for Dermatomyositis Fails to Meet Endpoints in Phase 2 Trial
The First Patient Has Been Dosed in the Third Cohort of a Phase I Trial For a Potential Parkinson’s Disease Treatment
ColiN00B / Pixabay

The First Patient Has Been Dosed in the Third Cohort of a Phase I Trial For a Potential Parkinson’s Disease Treatment

The first patient has undergone stem cell transplant treatment in the third cohort of a Phase I clinical study of the experimental treatment ISC-hpNSC for Parkinson’s disease. The full article can…

Continue Reading The First Patient Has Been Dosed in the Third Cohort of a Phase I Trial For a Potential Parkinson’s Disease Treatment